Third-Line Treatment Options for Metastatic Colorectal Cancer - Episode 6

Navigating Toxicities: Trifluridine-Tipiracil Plus Bevacizumab

December 5, 2024

Marwan G. Fakih, MD, City of Hope, Nilo Azad, MD

Panelists discuss the common toxicities associated with trifluridine-tipiracil plus bevacizumab in clinical practice, including their typical severity, and share their strategies for managing dose reductions and interruptions due to cytopenias when treating patients with this regimen.

EP. 1: Navigating mCRC: Treatment Options in the Third-Line Setting

EP. 2: Nuances With Defining “Refractory” mCRC in the Third-Line Setting

EP. 3: Treatment Sequencing in mCRC: Balancing Expert Perspectives and Shared Decision-Making With Patients

EP. 4: Perspectives on the SUNLIGHT Trial: Study Design and Outcomes

EP. 5: Factoring in Health-Related Quality of Life Outcomes in mCRC Treatment Selection

Now Viewing

EP. 6: Navigating Toxicities: Trifluridine-Tipiracil Plus Bevacizumab

EP. 7: Dosing Trifluridine-Tipiracil (TAS-102) Plus Bevacizumab Considerations: Hepatic or Renal Impairment

EP. 8: Unmet Needs in Third-Line mCRC: Challenges and Opportunities

Let’s further discuss these agents’ safety profiles and management strategies.… Dr Fakih, could you please discuss common toxicities that clinicians may see with trifluridine-tipiracil plus bevacizumab in their day-to-day practice?
1. What is the usual severity?
2. What is your treatment strategy in terms of dose reduction and/or interruptions due to cytopenias with trifluridine-tipiracil plus bevacizumab?